Osteoporosis Risk with Semaglutide

Introduction to Semaglutide and Bone Health

The American Diabetes Association warns about SGLT2 inhibitors causing increased osteoporotic bone fractures, particularly recommending clinicians minimize their use in older adults at high fracture risk, noting that Ozempic (semaglutide) is a GLP-1 receptor agonist with different mechanisms and bone effects 1

The American Diabetes Association guidelines suggest that semaglutide can be used without specific bone-related concerns beyond standard osteoporosis screening in low fracture risk patients, but high fracture risk patients should be considered for baseline BMD assessment and closer monitoring 2
The American Diabetes Association recommends obtaining baseline BMD (DXA scan) in patients with pre-existing osteoporosis or high fracture risk before initiating semaglutide, and repeating BMD every 2 years in high-risk patients on semaglutide 2
Ensure adequate calcium (1,000-1,200 mg daily) and vitamin D (800-1,000 IU daily) supplementation, and implement weight-bearing exercise programs at least 3 days per week for 30 minutes, including resistance training, to mitigate potential bone loss 2
Consider bisphosphonate therapy in patients with established osteoporosis (T-score ≤ -2.5) who require semaglutide for diabetes or obesity management 2

Do not confuse SGLT2 inhibitors with GLP-1 receptor agonists, as only SGLT2 inhibitors have clear guideline warnings about fracture risk, according to the American Diabetes Association 1
Do not withhold semaglutide solely due to osteoporosis concerns in patients who would benefit from glycemic control or weight loss, as the bone effects appear manageable with appropriate monitoring and supplementation, although this is not explicitly stated by a specific guideline society in the provided text 1